全文获取类型
收费全文 | 1265篇 |
免费 | 52篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 32篇 |
妇产科学 | 31篇 |
基础医学 | 229篇 |
口腔科学 | 16篇 |
临床医学 | 128篇 |
内科学 | 288篇 |
皮肤病学 | 18篇 |
神经病学 | 170篇 |
特种医学 | 66篇 |
外科学 | 116篇 |
综合类 | 2篇 |
一般理论 | 1篇 |
预防医学 | 73篇 |
眼科学 | 16篇 |
药学 | 61篇 |
中国医学 | 2篇 |
肿瘤学 | 76篇 |
出版年
2024年 | 2篇 |
2023年 | 12篇 |
2022年 | 34篇 |
2021年 | 46篇 |
2020年 | 31篇 |
2019年 | 34篇 |
2018年 | 53篇 |
2017年 | 29篇 |
2016年 | 51篇 |
2015年 | 42篇 |
2014年 | 59篇 |
2013年 | 62篇 |
2012年 | 87篇 |
2011年 | 82篇 |
2010年 | 59篇 |
2009年 | 58篇 |
2008年 | 85篇 |
2007年 | 85篇 |
2006年 | 57篇 |
2005年 | 69篇 |
2004年 | 64篇 |
2003年 | 47篇 |
2002年 | 49篇 |
2001年 | 8篇 |
1999年 | 7篇 |
1998年 | 13篇 |
1997年 | 7篇 |
1996年 | 4篇 |
1995年 | 6篇 |
1994年 | 4篇 |
1993年 | 9篇 |
1992年 | 6篇 |
1991年 | 4篇 |
1990年 | 8篇 |
1989年 | 7篇 |
1988年 | 4篇 |
1987年 | 5篇 |
1986年 | 8篇 |
1985年 | 7篇 |
1984年 | 3篇 |
1983年 | 6篇 |
1982年 | 3篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1976年 | 3篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1972年 | 2篇 |
1971年 | 2篇 |
1970年 | 1篇 |
排序方式: 共有1332条查询结果,搜索用时 15 毫秒
21.
Allergen Component Specific IgE Measurement With the Immulite™ 2000 System: Diagnostic Accuracy and Intermethod Comparison 下载免费PDF全文
22.
23.
24.
Alessio Bruni Alessandro Stefani Marco Perna Paolo Borghetti Niccol Giaj Levra Elisa DAngelo Alessandra DOnofrio Laura Rubino Luca Frassinelli Viola Salvestrini Matteo Mariotti Filippo Alongi Alessandro Gonfiotti Lorenzo Livi Vieri Scotti 《Journal of thoracic disease》2020,12(12):7518
BackgroundThymoma is a rare mediastinal neoplasia. Surgery is the backbone of the treatment, but the role of postoperative radiotherapy (PORT) remains controversial. We aimed to obtain data on survival and safety in patients treated with PORT in three different Italian institutions.MethodsWe retrospectively analyzed 183 consecutive patients who underwent surgery from 1981 to 2015. According to the Masaoka-Koga staging system, 39.3%, 32.7%, 18.6% and 9.8% patients were in stage I, II, III and IV of disease, respectively. PORT was indicated in 114 patients (62.3%), while 69 subjects underwent surgery alone. Complete resection was obtained in 68 patients who underwent PORT. Adverse events (AEs) were graded according to CTCAE v4.0. We analyzed the recent literature to describe the current reports on PORT for resected thymoma.ResultsMean follow-up was 130 months (range, 3–417 months). Overall survival (OS) at 1-, 5- and 10-year from surgery was 98.3%, 90.2% and 69.7% respectively. One-, 5- and 10-year disease specific survival (DSS) was 98.9%, 92.3% and 89.8% respectively. Disease free survival (DFS) at 1, 5 and 10 years from surgery was 96.7%, 88.3% and 82.8% respectively. Univariate analysis showed that complete resection, cell histology A-AB-B1 and stages I–II were significant predictors of better DSS and DFS. Multivariate analysis showed that sex, R0 margins and WHO histology was independent prognostic factors. Among patients treated with PORT, a trend towards better OS was evident with Masaoka stage I–II (P=0.09). Patients with R0 margins treated with PORT showed better OS and DSS (P=0.05). No differences in DSS for performance status (P=0.70), WHO histology (P=0.19), paraneoplastic syndrome (P=0.23) and surgical procedure (P=0.53) were evident. Patients treated with PORT had a higher level of acute AEs compared to surgery alone, but none of these was graded ≥3.ConclusionsOur results confirmed that patients with incompletely resected thymoma had the worst OS and DSS. High grade acute toxicity was not different between PORT and surgery alone. Other trials reported a significant benefit in OS, DSS and DFS in stage IIb–IV thymoma treated with PORT. 相似文献
25.
Factor replacement therapy with factor VIII (FVIII) concentrates is the current standard of care for patients with haemophilia A. Postadministration monitoring of FVIII activity during on‐demand or prophylactic treatment is important, for example to guide a suitable dosing regimen. While the use of two‐stage chromogenic substrate (CS) assays is increasing, activated partial thromboplastin time (APTT)‐based one‐stage clotting (OSC) assays are most commonly used to measure FVIII activity in clinical laboratories. Substantial variations in activity measurements have been observed in association with some OSC assay reagents when assessing extended half‐life FVIII molecules. Certain silica‐based APTT reagents have previously been shown to underestimate FVIII activity with the polyethylene glycol (PEG)‐conjugated product turoctocog alfa pegol (N8‐GP [ESPEROCT®]; Novo Nordisk A/S). As a wide range of assay reagents are used in clinical laboratories worldwide, it is essential to establish which can be used to accurately measure activity with modified FVIII concentrates. Here, we describe the approach taken by Novo Nordisk to determine the suitability and accuracy of assays and reagents to measure FVIII activity in samples that contain N8‐GP. While accurate activity measurements were possible with all tested CS assays and most of the OSC APTT reagents tested, three APTT reagents that contain silica as a contact activator were found to underestimate N8‐GP recovery (APTT‐SP, TriniCLOT?, STA® PTT‐Automate). The data demonstrate the importance of characterizing the accuracy of each FVIII activity assay. Any limitations should be communicated to treating physicians and the clinical laboratories that test samples containing N8‐GP. 相似文献
26.
27.
Vatreptacog alfa is a genetically engineered variant of recombinant factor VIIa (rFVIIa) containing three amino acid changes. Aspartic acid, valine, and glutamine residues replace valine, glutamic acid, and methionine at positions 158, 296, and 298, respectively. These substitutions result in considerable enhancement of the intrinsic (tissue factor-independent) capability to activate factor X and the downstream hemostatic events are consequently augmented. The beneficial effects of vatreptacog alfa have been demonstrated in numerous in vitro systems attempting to mimic hemophilia and corroborated in in vivo models. Vatreptacog alfa has successfully passed through phase 1 and 2 clinical trials and the molecule is currently being explored in phase 3 clinical trial for the treatment of bleedings in hemophilia patients with inhibitors. This article describes the proposed mechanism behind the increased activity and action of vatreptacog alfa and reviews available data, which suggest that vatreptacog alfa could be a valuable addition to the existing portfolio of treatment options for hemophilia patients with inhibitors. 相似文献
28.
We describe two cases, both presenting with a 2-year history of isolated language disorders, one compatible with logopenic variant and the other with non-fluent variant of primary progressive aphasia (PPA). Afterwards, each developed a corticobasal syndrome (CBS) with alien limb phenomenon and a multi-domain cognitive impairment. Regional cerebral perfusion (rCBF) study using 99mTc-ECD single photon emission computed tomography (SPECT) revealed hypoperfusion patterns consistent with these aphasia types and with the presence of limb apraxia. We report two cases of PPA variants associated with CBS and we suggest that SPECT rCBF correlates can be useful in making a differential diagnosis within the PPA spectrum. 相似文献
29.